

(c) Remarks

The claims are 17 and 18. Reconsideration of the claims is expressly requested.


Claims 13 and 16 were rejected over prior art. The rejection has been obviated by cancellation of these claims.

Claims 13-18 were provisionally rejected as an obviousness-type double patenting over claim 18 of Application No. 10/525,198, now U.S. Patent Publication No. US2006/0068221A1, published March 30, 2006. The rejection of claims 13-16 on this ground has been obviated by the cancellation of claims 13-16. The rejection is respectfully traversed.


With regard to present claims 17 and 18, they include formula [X] or formula [XI] in which a central fluorene unit or units is substituted by aryl or hetero amino groups. A fluorene ring has a fused structure of two phenyl rings sandwiching a central cyclopentane providing a tri-fused ring structure. The corresponding molecule in Application No. 10/525,198 is formula 1 which appears in claim 18 thereof as a result of its dependency on claims 4 and 17. Formula 1 in Application No. 10/525,198 has a central pyrene ring which is a structure characterized by four fused phenyl rings. Accordingly, formula 1 of claim 18 of Application No. 10/525,198 having a pyrene unit of 4 fused phenyl rings is different in kind from the instant formulae [X] or [XI] having a fluorene structure with three fused rings comprising two phenyl rings sandwiching a cyclopentyl ring.

Further, claim 18 though its dependency on Claim 4 of Application No. 10/525,198 includes a spiro compound of Formula [5] in which the spiro atom is a carbon.

atom bonded to connect two cyclopentane rings; i.e.



To the contrary, corresponding Formula [III] in present claims 17 and 18 is a spiro compound employing a silicon atom to connect the separate structures, i.e.



Therefore, in each of the key formulas of either of present claims 17 and 18, there is a significant difference in structure with the corresponding structure of claim 18 (17,4) of Application No. 10/525,198. Therefore, no double patenting exists, since no claim conflict is possible and one can practice the claimed invention of each without conflicting with the claims of the other.

There being no remaining issues the claims should be allowed and the case passed to issue.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Peter Saxon/
Peter Saxon
Attorney for Applicants
Registration No.: 24,947

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

FCIS_WS 1946038v1